PMID- 22752818
OWN - NLM
STAT- MEDLINE
DCOM- 20140422
LR  - 20220409
IS  - 0189-160X (Print)
IS  - 0189-160X (Linking)
VI  - 30
IP  - 5
DP  - 2011 Sep-Oct
TI  - Plasma homocysteine level and its relationship to clinical profile in Parkinson's 
      disease patients at the Lagos University Teaching Hospital.
PG  - 319-24
AB  - BACKGROUND: Hyperhomocysteinaemia (HHcy) is as a long-term sequelum of levodopa 
      therapy in Parkinson's disease (PD). Information on its frequency and effects in 
      Africans with PD is sparse. OBJECTIVE: To determine the frequency of HHcy and its 
      relationship to clinical features of PD in African patients. METHODS: Using a 
      case-control design, 40 consecutively attending PD patients and 40 age- and 
      gender-matched healthy volunteering controls were studied. Parkinson's disease 
      cases were evaluated for disease and treatment characteristics, using the Unified 
      Parkinson Disease Rating Scale (UPDRS) motor and activities of daily living 
      scores and disease stage (Hoehn and Yahr scale). Fasting total plasma 
      homocysteine (Hcy) was determined in all subjects. Hyperhomocysteinaemia was 
      defined as a Hcy level above the 90th percentile for the controls. RESULTS: Mean 
      Hcy was 13.8 +/- 5.4mmol/L in PD and 12.4+/-3mmol/L in controls (P>0.05). 
      Hyperhomocysteinaemia (Hcy > 16.26umol/L) occurred in nine (22.5%) PD patients 
      (all on levodopa) and 6 (15%) controls (P>0.05). Mean duration of levodopa use 
      was 92 +/- 105.3 months in PD with HHcy compared to PD patients with normal Hcy 
      33.9 +/- 33.2 (p < 0.05). Disease severity and disability were similar regardless 
      of Hcy levels. None of current age, disease duration, Hoehn and Yahr stage, UPDRS 
      scores, total levodopa dose and duration was independent predictor of 
      homocysteine level. CONCLUSION: There is increased occurrence of 
      hyper-homocysteinaemia in Nigerian subjects with Parkinson's disease, receiving 
      Levodopa. This hyperhomocysteinaemia is more common with prolonged use but 
      appears to have no relationship with disease severity or disability.
FAU - Ojo, O O
AU  - Ojo OO
AD  - Neurology Unit,Department of Medicine, College of Medicine,University of Lagos. 
      PMB 12003, Idi Araba, Lagos,Nigeria.
FAU - Oladipo, O O
AU  - Oladipo OO
FAU - Ojini, F I
AU  - Ojini FI
FAU - Sanya, E O
AU  - Sanya EO
FAU - Danesi, M A
AU  - Danesi MA
FAU - Okubadejo, N U
AU  - Okubadejo NU
LA  - eng
PT  - Journal Article
PL  - Nigeria
TA  - West Afr J Med
JT  - West African journal of medicine
JID - 8301891
RN  - 0 (Antiparkinson Agents)
RN  - 0LVT1QZ0BA (Homocysteine)
RN  - 46627O600J (Levodopa)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antiparkinson Agents/adverse effects/therapeutic use
MH  - Female
MH  - Homocysteine/*blood
MH  - *Hospitals, University
MH  - Humans
MH  - Hyperhomocysteinemia/*blood/chemically induced/epidemiology
MH  - Incidence
MH  - Levodopa/adverse effects/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Nigeria/epidemiology
MH  - Parkinson Disease/*blood/drug therapy
MH  - Retrospective Studies
EDAT- 2012/07/04 06:00
MHDA- 2014/04/23 06:00
CRDT- 2012/07/04 06:00
PHST- 2012/07/04 06:00 [entrez]
PHST- 2012/07/04 06:00 [pubmed]
PHST- 2014/04/23 06:00 [medline]
PST - ppublish
SO  - West Afr J Med. 2011 Sep-Oct;30(5):319-24.